Charles River Laboratories International (CRL) Income from Non-Controlling Interests (2009 - 2026)
Charles River Laboratories International (CRL) posted Income from Non-Controlling Interests of $722000.0 for Q2 2026, up 1660.98% on a QoQ basis from $41000.0 in Q1 2026, and up 96.73% year-over-year from $367000.0 in Q2 2025.
Analysis
Charles River Laboratories International (CRL) Income from Non-Controlling Interests (2009 - 2026) Analysis & Trends
Charles River Laboratories International has reported Income from Non-Controlling Interests for 18 years, with the latest figure at $722000.0 in Q2 2026.
- On a quarterly basis, Income from Non-Controlling Interests rose 96.73% year-over-year to $722000.0 in Q2 2026; TTM through Jun 2026 was $2.2 million, a 0.0% change from a year earlier, with the FY2025 full-year figure at $2.2 million, down 29.57% from the prior year.
- Income from Non-Controlling Interests was $722000.0 for Q2 2026 at Charles River Laboratories International, up from $41000.0 in the prior quarter.
- The five-year high for Income from Non-Controlling Interests was $2.4 million in Q3 2023, with the low at $41000.0 in Q1 2026.
- Average Income from Non-Controlling Interests over 5 years is $1.0 million, with a median of $785500.0 recorded in 2023.
- The sharpest annual moves came in 2024 and 2025: Income from Non-Controlling Interests slumped 92.57% in 2024, then soared 103.89% in 2025.
- Over 5 years, Income from Non-Controlling Interests stood at $1.7 million in 2022, then advanced by 10.14% to $1.9 million in 2023, then plunged by 59.96% to $748000.0 in 2024, then sank by 64.57% to $265000.0 in 2025, then soared by 172.45% to $722000.0 in 2026.
- The last three Income from Non-Controlling Interests figures came in at $722000.0 (Q2 2026), $41000.0 (Q1 2026), and $265000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.72 Bn | 42.64 Bn | 1.44 Bn | 2.00 Mn |
| 2 | Medpace Holdings | 17.37 Bn | 16.87 Bn | 201.64 Mn | - |
| 3 | Icon | 13.65 Bn | 12.72 Bn | 479.29 Mn | 19.44 Mn |
| 4 | Charles River Laboratories International | 13.13 Bn | 12.94 Bn | 452.07 Mn | 722,000.00 |
| 5 | Fortrea Holdings | 1.89 Bn | 1.72 Bn | 139.20 Mn | - |
| 6 | Evotec SE | 574.75 Mn | 148.87 Mn | - | - |
| 7 | Ginkgo Bioworks Holdings | 439.63 Mn | 355.09 Mn | 18.44 Mn | - |
| 8 | Champions Oncology | 69.43 Mn | 65.03 Mn | 7.70 Mn | - |
| 9 | MindWalk Holdings | 51.76 Mn | 46.29 Mn | 1.61 Mn | - |
| 10 | VivoSim Labs | 1.37 Mn | 1.37 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 27, 2026 | 722,000.00 |
| Mar 28, 2026 | 41,000.00 |
| Dec 27, 2025 | 265,000.00 |
| Sep 27, 2025 | 1.13 Mn |
| Jun 28, 2025 | 367,000.00 |
| Mar 29, 2025 | 409,000.00 |
| Dec 28, 2024 | 748,000.00 |
| Sep 28, 2024 | 638,000.00 |
| Jun 29, 2024 | 180,000.00 |
| Mar 30, 2024 | 1.52 Mn |
| Dec 30, 2023 | 1.87 Mn |
| Sep 30, 2023 | 632,000.00 |
| Jul 1, 2023 | 2.42 Mn |
| Apr 1, 2023 | 823,000.00 |
| Dec 31, 2022 | 1.70 Mn |
| Sep 24, 2022 | 1.14 Mn |
| Jun 25, 2022 | 1.34 Mn |
| Mar 26, 2022 | 2.20 Mn |
| Dec 25, 2021 | 2.25 Mn |
| Sep 25, 2021 | 1.73 Mn |